Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.

Journal of immunology (Baltimore, Md. : 1950) - 1 Jul 2016

Schatz-Jakobsen Janus Asbjørn, Zhang Yuchun, Johnson Krista, Neill Alyssa, Sheridan Douglas, Andersen Gregers Rom

Abstract excerpt

Eculizumab is a humanized mAb approved for treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Eculizumab binds complement component C5 and prevents its cleavage by C5 convertases, inhibiting release of both the proinflammatory metabolite C5a and formation of the membrane attack complex via C5b. In this study, we present the crystal structure of the complex...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Atypical Hemolytic Uremic Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement Activation

Share to Complement C5

Share to Crystallography, X-Ray

Share to Hemoglobinuria, Paroxysmal

Share to Hemolysis

Share to Immunoglobulin Fab Fragments

Source

Identifiers

PMID: 27194791
DOI: 10.4049/jimmunol.1600280

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.PMID 27194791Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement systemSemantic proximity Read ↗

Genetic Variants in C5 and Poor Response to EculizumabSemantic proximity Read ↗

Stratification of responders towards eculizumab using a structural epitope mapping strategy.Semantic proximity Read ↗

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapySemantic proximity Read ↗

With complements: C3 inhibition in the clinicSemantic proximity Read ↗

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaSemantic proximity Read ↗

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activationSemantic proximity Read ↗

Multifaceted Activities of Seven Nanobodies against Complement C4bSemantic proximity Read ↗

How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.Semantic proximity Read ↗

Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.